Advisors Asset Management Inc. Has $2.27 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Advisors Asset Management Inc. increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,646 shares of the biopharmaceutical company’s stock after acquiring an additional 2,174 shares during the period. Advisors Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $2,269,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after buying an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after acquiring an additional 209,530 shares during the last quarter. American Century Companies Inc. raised its stake in Halozyme Therapeutics by 9.7% during the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock worth $43,002,000 after acquiring an additional 72,544 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Halozyme Therapeutics by 37.8% in the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock worth $36,449,000 after acquiring an additional 191,030 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 60,000 shares of company stock valued at $3,425,000 over the last quarter. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HALO. TD Cowen lifted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Finally, Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $49.00 on Monday. The company has a market capitalization of $6.23 billion, a PE ratio of 16.23, a P/E/G ratio of 0.42 and a beta of 1.29. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The company has a 50 day simple moving average of $54.58 and a two-hundred day simple moving average of $53.57.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.